Immunochemotherapy Rchop In Patients With Diffuse Large B-Cell Lymphoma Over 75 Year Old.

e19525 Background: Median age of patients (pts) with diffuse large B cell lymphoma (DLBCL) is 65 years and the prevalence of DLBCL in pts aged over 75 years is rapidly growing. In younger patients, standard induction RCHOP immunotherapy results in about 70% of cure. On the other hand, older pts are frequently considered unfit for standard RCHOP treatment, and receive reduced doses of doxorubicin or a drug substituted with other agents. Methods: Between 2007 and 2011, 69 DLBCL pts (male - 35) over 75 year old were treated with standard RCHOP induction regimen in two academic centers. Patient characteristics: median age (range) 80(76-90), ECOG PS 0-1 – 83%, more than one comorbid condition – 64%, Ann Arbor stage III/IV - 39%, extranodal involvement – 81%, elevated LDH level - 43% of pts. Median number of RCHOP cycles was 6 (range 1-8). RCHOP dose reduction, mostly doxorubicin, was required in 27 pts (39%) Results: In 65 pts evaluable for response, ORR was 95%, and CR was 66%. 25 pts were hospitalized due to...